Evidence map›Paper›PMID 35399819›Full record

ReviewPhytomedicine plus : international journal of phytotherapy and phytopharmacology2021

Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.

Chengyuan Liang, Nan Hui, Yuzhi Liu, Guaiping Qiao, Juan Li, Lei Tian, Xingke Ju, Minyi Jia, Hong Liu, Wenqiang Cao and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Phytomedicine plus : international journal of phytotherapy and phytopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 40 citations in OpenAlex.

  1. Dynamic Chemical Profiling ofFoods (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Licorice extract inhibits porcine epidemic diarrhea virusThe Journal of general virology · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Chengyuan LiangFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Nan HuiFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Yuzhi LiuFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Guaiping QiaoFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Juan LiFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Lei TianFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Xingke JuFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Minyi JiaFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Hong LiuZhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, PR China.
Wenqiang CaoZhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, PR China.
Pengcheng YuSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
Han LiFaculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China.
Xiaodong RenMedical College, Guizhou University, Guiyang 550025, PR China.
Shaanxi University of Science and Technology · CNChina Pharmaceutical University · CNGuizhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In December 2019, a novel coronavirus, SARS-CoV-2 caused a series of acute atypical respiratory diseases worldwide. However, there is still a lack of drugs with clear curative effects, and the clinical trial research of vaccines has not been completely finished. Purpose: LH capsules are approved TCM patent medicine that are widely used for the treatment of respiratory tract infectious diseases caused by colds and flu. On April 12, 2020, LH capsules and granules were officially repurposed by the China Food and Drug Administration (CFDA) for patients with mild COVID-19 based on their safety and efficacy demonstrated through multicentre, randomized, controlled clinical trials. We hope to conduct a comprehensive review of it through modern pharmacy methods, and try to explain its possible mechanism. Methods: Using the full names of LH capsules Lianhuaqingwen, Lianhua Qingwen andSARS-COV-2, COVID-19 as the keywords of the search terms, systemically search for existing related papers in various databases such as Web of Science and PubMed. And completed the collection of clinical data in ClinicalTrials.gov and Chinese Clinical Trial Registry. Last but not least, we have sorted out the anti-inflammatory and antiviral mechanisms of LH capsules through literature and Selleck. Results: This review systematically sorted out the active ingredients in LH capsules. Furthermore, the related pharmacological and clinical trials of LH capsule on SARS-CoV-2, IAV and IBV were discussed in detail. Moreover, the present review provides the first summary of the potential molecular mechanism of specific substances in LH capsules involved in resistance to SARS-COV-2 infection and the inhibition of cytokine storm syndrome (CSS) caused by IL-6. Conclusion: This review summarizes the available reports and evidence that support the use of LH capsules as potential drug candidates for the prevention and treatment of COVID-19. However, TCM exerts its effects through multiple targets and multiple pathways, and LH capsules are not an exception. Therefore, the relevant mechanisms need to be further improved and experimentally verified.

Indexed as

3C-like protease (3CLpro)3CLpro, 3C-like proteaseACE2, Angiotensin-converting enzyme 2AECOPD, Acute exacerbation of chronic obstructive pulmonary diseaseAIDS, Acquired immune deficiency syndromeAQP3, Aquaporins 3ARDS, Acute respiratory distress syndromeCAT, COPD assessment testCC50, 50% Cytotoxic concentrationCCL-2/MCP-1, C—C motif ligand 2/monocyte chemoattractant protein-1CFDA, China Food and Drug AdministrationCOPD, Chronic obstructive pulmonary diseaseCOVID-19COVID-19, Coronavirus disease 2019CPE, Cytopathic effectCSS, Cytokine storm syndromeCT, Computed tomographyCXCL-10/IP-10, C-X-C Motif Chemokine Ligand 10/ Interferon Gamma-induced Protein 10Cytokine storm syndrome (CSS)DMSO, Dimethyl sulfoxideE protein, Envelope proteinERK, Extracellular signal-regulated kinaseFBS, Fatal bovine serumForsythia honeysuckle (Lianhuaqingwen,LH) capsulesgp-130, Glycoprotein 130Grb2, Growth factor receptor-bound protein 2Hep-2, Human epithelial type 2HIV, Human immunodeficiency virusHPLC, High-performance liquid chromatographyHSV-1, Herpes simplex virus type 1Huh-7, Human Hepatocellular Carcinoma-7HVJ, Hemagglutinating virus of JapanIAV, Influenza A virusIBV, Influenza B virusIC50, 50% Inhibition concentrationIFN-λ1, Interferon-λ1IL-6, Interleukin-6IL-6R, IL-6 ReceptorIL-8, Interleukin-8IP-10, Interferon-inducible protein-10JAK1/2, Janus kinase1/2JAK/STAT, Janus kinase/signal transducers and activators of transcriptionLD50, 50% Lethal doseLH capsules, Forsythia honeysuckle (Lianhuaqingwen) capsulesMAPK, Mitogen-activated protein kinaseMCP-1, Monocyte chemotactic protein 1MDCK, Madin-darby canine kidneyMEK, Mitogen-activated protein kinase kinaseMERS, Middle east respiratory syndromemIL-6R, Membrane-bound form IL-6 ReceptorMIP-1β, Macrophage Inflammatory Protein-1βMLD50, 50% Minimum lethal doseMOF, Multifunctional organ damageMOI, Multiplicity of infectionM protein, Membrane proteinmTOR, Mammalian target of rapamycinMTT, Methyl Thiazolyl TetrazoliumNF-kB, Nuclear transcription factor kappa-BNHC, National Health Commissionnsps, Non-structural proteinsORFs, Open reading framesPBS, Phosphate buffered salinePHN, PhillyrinPI3K, Phosphoinositide 3-kinasesPKA/p-CREB, Protein kinase A /phosphorylated cAMP response element-binding proteinPKB, Akt, Protein kinase BPLpro, Papain-like proteasesPRC, People's Republic of ChinaQC, Quality controlqPCR, Quantitative PCRRANTES, Regulated on activation normal T cell expressed and secretedRas, Ras GTPaseRSV, Respiratory syncytial virusRT-PCR, Reverse transcription PCRSARS-CoV-2TCID50, 50% Tissue culture infective doseTD0, Non-toxic DoseTD50, Half-toxic doseVero E6, African Green Monkey Kidney Epithelial-6

Identifiers

PMID35399819
PMCPMC7833308
OpenAlexW3121458723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.